The therapeutic implications of these findings are profound, paving the way for novel diagnostic tools, such as PET probes for assessing PHGDH compartmentalization, and promoting a synergistic approach to "exercise-pharmacotherapy" in the treatment of Alzheimer's disease. Here, PHGDH is linked to early-onset autosomal dominant Alzheimer disease.